Sudarshan Pharma Industries
- Market cap
- ₹ 779 Cr.
- P/E
- 38.1x
- P/B
- 5.05x
- 52-week range
- 18.5 – 42.79
- ROE
- 16%
- ROCE
- 15%
- Dividend yield
- 0%
- Debt / equity
- 1.84
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- BSE SME
About
Sudarshan Pharma Industries Limited is an India-based company, which is engaged in manufacturing, having a plant for API and doing jobwork manufacturing in Pharmaceutical Items and traders in Chemicals and Solvents in India. The Company is involved in specialty chemicals and intermediates for pharma, agricultural chemicals, coating, paints, adhesive, and various other industries. It is also focused on active pharmaceutical ingredient manufacturing. It is also into specialty chemicals imports and exports, as well as supplying the same to the actual users. The Company provides customized specialty chemicals to its clients in India and abroad regularly. The Company is involved in contract manufacturing, outsourcing and supplying generic pharma formulations and medicines to healthcare institutions, governments, non-governmental organizations (NGO) and hospitals. The Company operates in the states of Maharashtra, Gujarat and Uttarakhand.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Sudarshan Pharma Industries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)38.1 against a typical 25.8: pricier than most peers (1st = cheapest).89th of 129
- Sales growth+20.1% against a typical +25.9% from a year earlier.69th of 112
- Profit growth+41.7% against a typical +42.4% from a year earlier.52nd of 102
- Share price, 3 months−6% against a typical −5.8%.60th of 118
- Size₹ 779 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).50th of 126
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 129 | 116 | 162 | 145 | 169 | 168 | 221 | 174 |
| Expenses | 97 | 116 | 108 | 146 | 134 | 160 | 157 | 201 | 159 |
| Operating Profit | 2 | 13 | 8 | 16 | 11 | 9 | 11 | 20 | 16 |
| OPM % | 2.1% | 10.2% | 6.9% | 9.9% | 7.6% | 5.5% | 6.5% | 9.1% | 9.1% |
| Other Income | 1 | −1 | 1 | −1 | 1 | 2 | 2 | 4 | 1 |
| Interest | 4 | 4 | 4 | 4 | 6 | 6 | 6 | 8 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −2 | 8 | 4 | 10 | 5 | 4 | 5 | 16 | 8 |
| Tax % | −21.9% | 24.9% | 24.9% | 25.1% | 26.8% | 8.5% | 20.2% | 27.4% | 25.3% |
| Net Profit | −1 | 6 | 3 | 7 | 4 | 4 | 4 | 11 | 6 |
| EPS in Rs | −0.05 | 0.24 | 0.12 | 0.31 | 0.17 | 0.17 | 0.18 | 0.45 | 0.23 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 33%
- 10 Years
- —
- 5 Years
- 54%
- 3 Years
- 48%
- TTM
- 13%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 65%
- TTM
- —
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sudarshan Pharma Industries | ₹ 38.00 | ₹ 779 Cr. | 38.1x | 5.1x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Hemal Vasantrai Mehta
- Managing Director, Executive Chairman of the Borad
- Sharad Govindrao Kathawate
- Chief Financial Officer
- Nirav Shah
- Compliance Officer, Company Secretary
- Indraraj Neogi
- Head of Sales and Marketing of Pharma Division
- Shrinivas Patil
- Exports
- Santosh Thakur
- Import Sourcing and Indenting
Prices are delayed and for information only. Nothing on this page is investment advice.